Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 128052

Sort by

Sort Order Select

Journal Articles

Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010

Simon Harrison, Phoebe Joy Ho, Sueh-Li Lim, Stephanie Talam, Hannah Pahl, Dharmesh Dingar, Scott Currence, Travis Quigley, Andrew Spencer

Blood (2025) 146 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2025-LBA-1

Published: 2025

Journal Articles

Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment

Blood (2025) 146 (Supplement 2): LBA-2.

https://doi.org/10.1182/blood-2025-LBA-2

Published: 2025

Journal Articles

Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients

Blood (2025) 146 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2025-LBA-3

Published: 2025

Journal Articles

Whole genome transcriptome sequencing in inherited bone marrow failure syndromes and related diseases – the ibmdx study

Blood (2025) 146 (Supplement 2): LBA-4.

https://doi.org/10.1182/blood-2025-LBA-4

Published: 2025

Journal Articles

A hospital policy of tranexamic acid to reduce transfusion in major non-cardiac surgery: The traction trial

Blood (2025) 146 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2025-LBA-5

Published: 2025

Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Blood (2025) 146 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2025-LBA-6

Published: 2025

Journal Articles

Effect of exercise on body composition and bone health in patients with thalassemia

Ellen Fung, Raquel Manzo, Emily Van Horn, Vivianna Preciado, Mohit Prasad, Angelos Resendez, Ashutosh Lal, Juliet Hagar, Jennifer Sherwood, Vanessa Yingling

Blood (2025) 146 (Supplement 1): 8228.

https://doi.org/10.1182/blood-2025-8228

Published: 2025

Journal Articles

Efficacy, safety, and pharmacokinetics of alpelisib (ALP) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS): Epik-P4, a Phase II study

Alexandra J Borst, Denise M Adams, Juan C Lopez-Gutierrez, Friedrich Kapp, Ines Vendrell, Fotis Polydoros, Elise Burmeister-Getz, Nydia Caro, Guillaume Canaud

Blood (2025) 146 (Supplement 1): 8227.

https://doi.org/10.1182/blood-2025-8227

Published: 2025

Journal Articles

The holistic trial: A comprehensive evaluation of two second-line therapeutic approaches for immune thrombocytopenia (ITP) – a pragmatic randomized controlled trial

Eirik Tjønnfjord, Inge Christoffer Olsen, Lamya Garabet, Hoa Tran, Doaa El Demerdash, Salam AlKindy, Geir Tjønnfjord, Waleed Ghanima

Blood (2025) 146 (Supplement 1): 8226.

https://doi.org/10.1182/blood-2025-8226

Published: 2025

Journal Articles

Suicide risk management protocol (SRMP) for presence trial in adolescents and young adults (AYAs) living with sickle cell disease (SCD) and chronic pain

Steffi Siebert, Laura De Castro, Charles Jonassaint, Amy Tiberi, Ana Radovic

Blood (2025) 146 (Supplement 1): 8225.

https://doi.org/10.1182/blood-2025-8225

Published: 2025

Journal Articles

The ‘αO2-PRBCThal’ trial on the use of hemanext One® for blood transfusion support transfusion-dependent thalassemia

Polyxeni Delaporta, Efthalia-Faidra Agiomavriti-Stephanopoulou, Elena Chatzikalil, Maria Sykioti, Sofia Giatsiatsiou, Konstantinos Stamoulis, Alkmini Anastasiadi, Vasileios Dendrinos, Pagona Flevari, Vasileios Tzounakas, Anastasios Kriebardis, Sofia Ioannidou, Maria Dimopoulou, Antonis Kattamis

Blood (2025) 146 (Supplement 1): 8224.

https://doi.org/10.1182/blood-2025-8224

Published: 2025

Journal Articles

Assessing the influence of live and online enduring CME activities presented at the 66th ASH annual meeting on hematology/oncology specialists using pre-/post-education evaluations

Michelle Worst, Heather Friedman, Sarah Bomba, Megan Whitney, Davecia Cameron, Stephanie Baumhover, Sanneke Koekkoek, Deb Middleton, Charlotte Warren, Yoji Yamaguchi, Haleh Kadkhoda, Nikolai Podoltsev

Blood (2025) 146 (Supplement 1): 8223.

https://doi.org/10.1182/blood-2025-8223

Published: 2025

Journal Articles

Gender disparities in first-author representation across ASH submissions 2019-2024

Bret Miller, Taha Huda, Cole Miller, Camelia Garcia, Kevin Velasquez, Parth Raina, Paola Brull-Hayes, Sara Khan, Alexander Gutierrez

Blood (2025) 146 (Supplement 1): 8222.

https://doi.org/10.1182/blood-2025-8222

Published: 2025

Journal Articles

Building a community of hematology department heads to foster peer support and managerial innovation

Roch Houot, Emmanuel Gyan

Blood (2025) 146 (Supplement 1): 8221.

https://doi.org/10.1182/blood-2025-8221

Published: 2025

Journal Articles

Impact of short-form, case-based continuing medical education on clinician knowledge and competence in optimizing CAR T-cell therapy for Relapsed/Refractory multiple myeloma

Meghan Coulehan, Aisha Suhail, Emily Kitterman, Jesús Berdeja, Adriana Rossi

Blood (2025) 146 (Supplement 1): 8220.

https://doi.org/10.1182/blood-2025-8220

Published: 2025

Journal Articles

Optimizing board exam outcomes: A structured exam preparation curriculum for hematology/oncology fellows

Sonia Godbole, Manan Shah, Rich Thompson, Arianna Henning, Danielle Zimmerman, Audrey Sigmund

Blood (2025) 146 (Supplement 1): 8219.

https://doi.org/10.1182/blood-2025-8219

Published: 2025

Journal Articles

From deficiency to competency: Strategies to strengthen classical hematology training across the United States

Jacob Schmelz, Usha Perepu

Blood (2025) 146 (Supplement 1): 8218.

https://doi.org/10.1182/blood-2025-8218

Published: 2025

Journal Articles

Trends in first-author retention in ASH accepted works from 2019–2024

Taha Huda, Bret Miller, Cole Miller, Kevin Velasquez, Camelia Garcia, Ziyad Razeq, Hamza Ajmal, Toni Fegahli, Sara Khan, Alexander Gutierrez

Blood (2025) 146 (Supplement 1): 8217.

https://doi.org/10.1182/blood-2025-8217

Published: 2025

Journal Articles

Transition to fellowship: A qualitative exploration of the experience of hematology-oncology fellowship at the university of Colorado

Lisa Chu, Ashley Dafoe, Brandon McMahon, Sarah Brewer

Blood (2025) 146 (Supplement 1): 8216.

https://doi.org/10.1182/blood-2025-8216

Published: 2025

Journal Articles

Analysis of published case reports on lymphoma using llms

Fabio Dennstaedt, Alin Handra, Nikola Cihoric

Blood (2025) 146 (Supplement 1): 8215.

https://doi.org/10.1182/blood-2025-8215

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment

Pirtobrutinib vs bendamustine plus rituximab (BR) in patients with CLL/SLL: First results from a randomized phase III study Examining a non-covalent BTK inhibitor in untreated patients

Whole genome transcriptome sequencing in inherited bone marrow failure syndromes and related diseases – the ibmdx study

A hospital policy of tranexamic acid to reduce transfusion in major non-cardiac surgery: The traction trial

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Effect of exercise on body composition and bone health in patients with thalassemia

Efficacy, safety, and pharmacokinetics of alpelisib (ALP) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS): Epik-P4, a Phase II study

The holistic trial: A comprehensive evaluation of two second-line therapeutic approaches for immune thrombocytopenia (ITP) – a pragmatic randomized controlled trial

Suicide risk management protocol (SRMP) for presence trial in adolescents and young adults (AYAs) living with sickle cell disease (SCD) and chronic pain

The ‘αO2-PRBCThal’ trial on the use of hemanext One® for blood transfusion support transfusion-dependent thalassemia

Assessing the influence of live and online enduring CME activities presented at the 66th ASH annual meeting on hematology/oncology specialists using pre-/post-education evaluations

Gender disparities in first-author representation across ASH submissions 2019-2024

Building a community of hematology department heads to foster peer support and managerial innovation

Impact of short-form, case-based continuing medical education on clinician knowledge and competence in optimizing CAR T-cell therapy for Relapsed/Refractory multiple myeloma

Optimizing board exam outcomes: A structured exam preparation curriculum for hematology/oncology fellows

From deficiency to competency: Strategies to strengthen classical hematology training across the United States

Trends in first-author retention in ASH accepted works from 2019–2024

Transition to fellowship: A qualitative exploration of the experience of hematology-oncology fellowship at the university of Colorado

Analysis of published case reports on lymphoma using llms

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only